| Name | Title | Contact Details |
|---|---|---|
Jeff Clair |
Chief Revenue Officer | Profile |
Corey Bodzin |
Senior Vice President of Product | Profile |
Chris Garcia |
Director Channel Sales, US | Profile |
Justin Talerico |
Chief Marketing Officer | Profile |
Ziad Fanous |
Chief Financial Officer | Profile |
Impexiums Association Management Solution (AMS) empowers associations to make better decisions, execute with precision and delight their members.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Retail Advantages Inc is a New Hamburg, ON-based company in the Software & Internet sector.
Attic Technologies is a Middlesex, NJ-based company in the Software and Internet sector.
Active Hosting is a San Francisco, CA-based company in the Software & Internet sector.